A VARIANT OF HUMAN PAPILLOMAVIRUS (HPV)
TYPE 66 IS COMMON AMONG HPV-INFECTED
WOMEN FROM THE REPUBLIC OF MACEDONIA
Duvlis S1, Plaseska-Karanfilska D1, Bashevska N2, Dimitrov G3,
Milanova E3, Naumov J3, Efremov GD1
*Corresponding Author: Dr. Dijana Plaseska-Karanfilska, Macedonian Academy of Sciences and Arts, Research Center for Genetic Engineering and Biotechnology, Av. Krste Misirkov 2, POB 428, 1000 Skopje, Republic of Macedonia; Tel: +389 2 120 253; Fax: +389 2 115 434; E-mail: dijana@manu.edu.mk page: 53
|
Abstract
Epidemiological and molecular studies have implicated the human papilloma virus (HPV) as the main risk factor for the development of cervical intraepithelial neoplasia (CIN) and cervical cancer. Currently, 45 HPV types are known to infect the genital tract, of which at least 10 are associated with cancer. For many new and rare HPV types the oncogenic potential is still unknown, due to the limited number of reports concerning their association with particular dysplastic and neoplastic lesions.
Here, we present the prevalence, association with cytological and histological cervical lesions and sequence variations of a variant of HPV 66 among Macedonian woman. Fifteen women or ~7.9% of the 190 HPV positive women in whom the HPV type was determined, were infected with the HPV 66 variant. Thus, this variant is the third most common type, after HPV 16 (~28.4%), and HPV 31 (12.1%), among Macedonian women. The DNA sequence analysis of the L1 region showed less than 2% difference from the published HPV 66 sequence, thus confirming that this virus is a variant of HPV type 66.
The results from the cytological and/or histological analyses showed that the HPV 66 was present in two women with normal cervical findings, one with non-specific chronic cervical inflammation, seven with low-grade squamous intraepithelial lesions (SIL) and five with high-grade SIL.
In conclusion, a variant of HPV 66 is a relatively common intermediate risk HPV type among Macedonian women with cervical abnormalities.
Key words: human papilloma virus (HPV), HPV 66 variant, cervical lesions, squamous intraepithelial lesions (SIL)
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|